Triviumvet DAC

TriviumVet Designated Activity Company is an innovative animal‑health organisation dedicated to developing therapeutic solutions for serious, often untreatable diseases in companion animals. By focusing on the unmet needs of dogs and cats, the company aims to extend the quality and length of the lives that pets share with the people who love them.

The firm’s pipeline spans several high‑impact therapeutic areas. In cardiology, TriviumVet has achieved FDA conditional approval for Felycin®‑CA1, a once‑weekly delayed‑release sirolimus tablet that manages ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy – the first conditionally approved drug for feline HCM. Ongoing projects include TRIV202, an mTOR‑inhibition platform for chronic inflammatory conditions; TRIV201, a beef‑flavoured neuropathic‑pain analgesic for dogs; TRIV209, a veterinary proton‑pump inhibitor for canine gastric ulceration; and TRIV307, an mTOR‑based therapy for chronic kidney disease in cats.

Beyond product development, TriviumVet actively recruits pet owners to participate in its clinical trials, recognising that collaborative research is essential to raise the standard of care for the most debilitating pet diseases. The company’s work is driven by the everyday joy of a purr, a bark or a slobbery kiss, and by the belief that every pet deserves the best possible treatment.